117 related articles for article (PubMed ID: 21270522)
1. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
Donia M; Maksimovic-Ivanic D; Mijatovic S; Mojic M; Miljkovic D; Timotijevic G; Fagone P; Caponnetto S; Al-Abed Y; McCubrey J; Stosic-Grujicic S; Nicoletti F
Cell Cycle; 2011 Feb; 10(3):492-9. PubMed ID: 21270522
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.
Rothweiler F; Michaelis M; Brauer P; Otte J; Weber K; Fehse B; Doerr HW; Wiese M; Kreuter J; Al-Abed Y; Nicoletti F; Cinatl J
Neoplasia; 2010 Dec; 12(12):1023-30. PubMed ID: 21170266
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.
Mijatovic S; Maksimovic-Ivanic D; Mojic M; Timotijevic G; Miljkovic D; Mangano K; Donia M; Di Cataldo A; Al-Abed Y; Cheng KF; Stosic-Grujicic S; Nicoletti F
J Cell Physiol; 2011 Jul; 226(7):1803-12. PubMed ID: 21506111
[TBL] [Abstract][Full Text] [Related]
4. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.
Donia M; Mangano K; Fagone P; De Pasquale R; Dinotta F; Coco M; Padron J; Al-Abed Y; Giovanni Lombardo GA; Maksimovic-Ivanic D; Mijatovic S; Zocca MB; Perciavalle V; Stosic-Grujicic S; Nicoletti F
Oncol Rep; 2012 Aug; 28(2):682-8. PubMed ID: 22665020
[TBL] [Abstract][Full Text] [Related]
5. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.
Maksimovic-Ivanic D; Mijatovic S; Miljkovic D; Harhaji-Trajkovic L; Timotijevic G; Mojic M; Dabideen D; Cheng KF; McCubrey JA; Mangano K; Al-Abed Y; Libra M; Garotta G; Stosic-Grujicic S; Nicoletti F
Mol Cancer Ther; 2009 May; 8(5):1169-78. PubMed ID: 19417156
[TBL] [Abstract][Full Text] [Related]
6. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
Mojic M; Mijatovic S; Maksimovic-Ivanic D; Dinic S; Grdovic N; Miljkovic D; Stosic-Grujicic S; Tumino S; Fagone P; Mangano K; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
Cell Cycle; 2012 Mar; 11(6):1174-82. PubMed ID: 22370480
[TBL] [Abstract][Full Text] [Related]
7. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.
Pajonk F; Himmelsbach J; Riess K; Sommer A; McBride WH
Cancer Res; 2002 Sep; 62(18):5230-5. PubMed ID: 12234989
[TBL] [Abstract][Full Text] [Related]
8. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
Mojic M; Mijatovic S; Maksimovic-Ivanic D; Miljkovic D; Stosic-Grujicic S; Stankovic M; Mangano K; Travali S; Donia M; Fagone P; Zocca MB; Al-Abed Y; McCubrey JA; Nicoletti F
Mol Pharmacol; 2012 Oct; 82(4):700-10. PubMed ID: 22798453
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells.
Pereira M; Vale N
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293096
[TBL] [Abstract][Full Text] [Related]
11. The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
Maksimovic-Ivanic D; Mojic M; Bulatovic M; Radojkovic M; Kuzmanovic M; Ristic S; Stosic-Grujicic S; Miljkovic D; Cavalli E; Libra M; Fagone P; McCubrey J; Nicoletti F; Mijatovic S
Leuk Res; 2015 Oct; 39(10):1088-95. PubMed ID: 26220866
[TBL] [Abstract][Full Text] [Related]
12. Saquinavir-NO inhibits IL-6 production in macrophages.
Momčilović M; Mangano K; Jevtić B; Mammana S; Stošić-Grujičić S; Nicoletti F; Miljković D
Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):499-506. PubMed ID: 24842127
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
15. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
Shankar S; Chen X; Srivastava RK
Prostate; 2005 Feb; 62(2):165-86. PubMed ID: 15389801
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
[TBL] [Abstract][Full Text] [Related]
18. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
Chavanet P; Piroth L; Grappin M; Buisson M; Gourdon F; Cabié A; Duong M; Brunel-Dalmas F; Peytavin G; Portier H
HIV Clin Trials; 2001; 2(5):408-12. PubMed ID: 11673815
[TBL] [Abstract][Full Text] [Related]
19. Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.
Huerta-Yepez S; Baritaki S; Baay-Guzman G; Hernandez-Luna MA; Hernandez-Cueto A; Vega MI; Bonavida B
Nitric Oxide; 2013 Feb; 29():17-24. PubMed ID: 23246440
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
